Needham & Company LLC Reiterates Hold Rating for Shattuck Labs (NASDAQ:STTK)

Shattuck Labs (NASDAQ:STTK)‘s stock had its “hold” rating reissued by Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Thursday. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Finally, Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target for the company. Four analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Shattuck Labs has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $1.06 on Thursday. The company has a market capitalization of $50.37 million, a price-to-earnings ratio of -0.69 and a beta of 1.66. The company’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.49. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. Equities analysts expect that Shattuck Labs will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors have recently added to or reduced their stakes in the business. Zacks Investment Management purchased a new stake in shares of Shattuck Labs during the 4th quarter worth $25,000. Virtu Financial LLC purchased a new stake in Shattuck Labs in the 4th quarter valued at approximately $30,000. Atom Investors LP acquired a new stake in Shattuck Labs during the 3rd quarter valued at $35,000. Readystate Asset Management LP purchased a new position in Shattuck Labs during the third quarter worth $39,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.